Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575393 | 0.93 | WNT3A (0.51) | WNT3ALMNASMN1; SMN2MGLLALDH1A1 | |
| SCHEMBL3576763 | 0.92 | HDAC1 (0.49) | SMN1; SMN2MGLLALDH1A1TDP1KDM4E | |
| SCHEMBL3560359 | 0.89 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL3566111 | 0.89 | HDAC1 (0.47) | MAPTHDAC1 | |
| SCHEMBL3576784 | 0.89 | MGLL (0.48) | LMNASMN1; SMN2MGLLALDH1A1GAA | |
| SCHEMBL3576103 | 0.87 | POLB (0.53) | LMNASMN1; SMN2ALDH1A1GAANPSR1 | |
| SCHEMBL1892705 | 0.85 | HDAC1 (0.57) | LMNASMN1; SMN2ALDH1A1GAANPSR1 | |
| SCHEMBL3568042 | 0.84 | HDAC1 (0.49) | SMN1; SMN2MGLLALDH1A1TDP1KDM4E | |
| SCHEMBL3573597 | 0.81 | MGLL (0.48) | LMNASMN1; SMN2MGLLALDH1A1GAA | |
| SCHEMBL3573179 | 0.81 | HDAC1 (0.47) | WNT3AALDH1A1KDM4EMAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | claimed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1874295-A4 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1874295-A1 | BENZOTHIOPHENE DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | WNT3A 4473/4885LMNA 3991/4885SMN1; SMN2 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.